Neuroscience drug development in a French mid-sized pharmaceutical company
Neuroscience is a notoriously difficult domain in which to develop new medicines for patients. It is one of the highest medical needs in the world today, with many complex and hard-to-treat diseases having almost no treatment options available. This talk will explain, with some clear case studies, some ways in which we can try to mitigate the risks and improve the probability of success in developing new medicines for these patients. It will cover the identification of new targets, including some of the core biology in neuroscience that we know contributes to pathology, alongside the methods we use to drug these targets and how we then develop these drugs in animal and human studies to demonstrate they are safe and effective in treating disease.
Ross Jeggo
Ross is a neuroscientist who completed his PhD at the Royal Free Hospital in London. He then joined a start-up biotechnology company based at the University of Warwick, where he worked for 11 years across almost all areas of neuroscience providing contract research and developing new treatment approaches for neuropathic pain. He then moved to the pharmaceutical industry, starting with three years in Copenhagen with the Neuroscience company Lundbeck, before joining Servier in Paris in 2017, where he leads the Neurology Therapeutic Area in the research and development department.